This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues
by Swarup Gupta
The Dow traded inside a tight band during a week marked by key earnings releases and legislative developments.
Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?
by Zacks Equity Research
Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.
Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.
Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.
Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.
Pfizer and Apple In Focus
by Zacks Equity Research
Pfizer and Apple In Focus
On Pfizer and Apple: 2 Titanic Stocks Reporting Earnings Today
by Mark Vickery
Instead of another run-down of the high number of companies reporting today, I'd like to focus on one company having reported before the bell and one coming after the close: Pfizer (PFE) and Apple (AAPL).
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook
Pfizer (PFE) Tops Q1 Earnings Estimates, Misses Sales
by Zacks Equity Research
PFE beat first quarter earnings which came in at 69 cents while our consensus called for EPS of 67 cents.
Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD
by Zacks Equity Research
The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.
The Week Ahead In One Click
by Brian Bolan
A look at the important economic data and earnings that are headed your way this week.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
Should You Buy Pfizer (PFE) Ahead of Earnings?
by Zacks Equity Research
Pfizer (PFE) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More
by Arpita Dutt
Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
by Sweta Killa
Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
Is J&J's Pharma Sales Slowdown a Warning for Other Players?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Lackluster J&J Q1 Pushes Healthcare ETFs Down
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales.
Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.